SynthesisEuropean journal of clinical pharmacology2026
The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis review aimed to assess the efficacy and safety of letrozole, administered either as monotherapy or combined with methotrexate, for the treatment of ectopic pregnancy (EP).
methodsFollowing established guidelines (PRISMA), a systematic review and meta-analysis was conducted. Major online research databases (Web of Science, PubMed, Scopus, and Cochrane Library) were searched for studies comparing letrozole to methotrexate in women diagnosed with EP via ultrasound, from the earliest available records up to November 5, 2024. The combined results were analyzed using risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI). The quality of the included studies was evaluated using ROB-2 and ROBINS-I tools.
resultsEight studies (five randomized and three non-randomized trials) involving 548 participants were included. Letrozole monotherapy achieved a higher treatment success rate compared to methotrexate (6 studies, 376 patients, RR 1.10, 95% CI [1.01, 1.20], p = 0.03). Combining letrozole with methotrexate showed comparable success rates to methotrexate alone (2 studies, 161 patients, RR 1.09, 95% CI [0.96, 1.23], p = 0.17). On day 4, β-human chorionic gonadotropin (β-hCG) levels decreased faster in both the letrozole monotherapy (5 studies, 291 patients, MD -131.15 mIU/mL, 95% CI [-220.77, -41.52], p = 0.004) and combination groups (2 studies, 136 patients, MD -188.79 mIU/mL, 95% CI [-242.07, -135.52], p < 0.00001). Letrozole monotherapy resulted in a smaller reduction in platelet count (2 studies, 76 patients, MD 81.61 × 10³/µL, 95% CI [40.11, 123.10], p = 0.0001) and better-preserved liver enzymes, such as ALT (3 studies, 76 patients, MD -21.27 IU/L, 95% CI [-24.42, -18.12], p < 0.00001). No differences were noted in anti-Müllerian hormone (AMH) levels (2 studies, 39 patients, MD -0.01 ng/mL, 95% CI [-0.40, 0.38], p = 0.97).
conclusionsLetrozole, especially when used as the only treatment, may be a more effective and potentially safer alternative to methotrexate for medically treating EP. However, larger, higher-quality research studies are necessary to confirm these findings and to determine the best way to use letrozole.
Indexed as
Identifiers
42362983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.